October 31, 2008
Biovest Signs Distribution Agreement With Idis
Biovest International, a majority-owned subsidiary of Accentia Biopharmaceuticals, has executed a distribution agreement with Idis, a European drug distributor, to exclusively supply BiovaxID, a personalized, anti-idiotype cancer vaccine, under a named-patient program in France, Germany, Italy, Greece, Spain and the UK.
Under the terms of this agreement, sales of BiovaxID are expected to commence in the first calendar quarter of 2009, with the anticancer vaccine being made available to those patients suffering from various B-cell related blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma, multiple myeloma, and non-Hodgkin's lymphoma.
BiovaxID is said to be designed to stimulate a patient's immune system to recognize and destroy cancerous B-cells associated with blood-related malignancies.
Steven Arikian, chairman and CEO of Biovest, said: "A named-patient program is a compassionate-use drug access program under which physicians can legally prescribe investigational drugs to qualifying patients.
"Under this program, investigational drugs are administered to patients who are suffering from serious illnesses until the drug is approved by the European Medicines Agency. The named-patient program will make BiovaxID available to patients with various B-cell related blood cancers."